Evidence map›Paper›PMID 42222550›Full record

ReviewBasic and clinical neuroscience

Histopathological Effects of the Intrathecal Chondroitinase ABC Administration in Spinal Cord Injured Rats: A Systematic Review.

Mohammad Amin Habibi, Ali Anjomshoa, Mohsen Sadeghi-Naini, Zahra Ghodsi, Samuel Berchi Kankam, Erfan Razavi, Armin Aryannejad, Seyed Mohammad Piri, Akam Ramezani, Rasha Atlasi and 9 more

Abstract readReview
In one paragraph

Review in Basic and clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Mohammad Amin HabibiSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0009-0005-0934-4015
Ali AnjomshoaSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Mohsen Sadeghi-NainiDepartment of Neurosurgery, School of Medicine, Lorestan University of Medical Sciences, Khorram Abad, Iran.ORCID 0000-0003-1832-9042
Zahra GhodsiSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1381-9926
Samuel Berchi KankamSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1682-160X
Erfan RazaviStudents' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Armin AryannejadExperimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1354-5566
Seyed Mohammad PiriSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-8262-9846
Akam RamezaniStudents' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-1535-0025
Rasha AtlasiEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-9118-5324
Kawthar MohamedSchool of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Sina ShooSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Meysam KavehStudents' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-8129-1668
Akbar FotouhiDepartment of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0002-6438-6833
Arman ZeinaddiniSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.
James S HarropDepartment of Neurological and Orthopedic Surgery, Thomas Jefferson University, Philadelphia, United States.ORCID 0000-0002-0943-3406
Alex R VaccaroDepartment of Orthopedics and Neurosurgery, Thomas Jefferson University, Philadelphia, United States.ORCID 0000-0002-8073-0796
Michael G FehlingsSpinal Program, Toronto Western Hospital, University Health Network, Toronto, Canada.
Vafa Rahimi-MovagharSina Trauma and Surgery Research Center, Tehran University of Medical Sciences, Tehran, Iran.ORCID 0000-0001-7347-8767

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chondroitinase ABC (ChABC) has been considered a potential treatment for spinal cord injury (SCI). We aim to identify and evaluate the histopathological effects of intrathecal ChABC administration in SCI rat models. Methods: We searched PubMed/MEDLINE, Scopus, Web of Science, Embase, and Cochrane Library for studies published from the inception of each database until November 22, 2022. Results: Of 3857 screened citations, 17 studies met eligibility criteria and were entered into the qualitative analysis. Sixteen studies were of high quality, and one study was of medium quality. The four main rat strains used in studies were Sprague-Dawley, Wistar, Lister hooded, and Long-Evans. ChABC treatment phases were considered acute (within 24 hours after injury), subacute (5 or 7 days after injury), or chronic (4 or 6 weeks after injury). Accordingly, ChABC administration in the acute phase of injury significantly reduced cyst formation and promoted tissue preservation and sensory neuron plasticity. Regardless of the treatment phase, ChABC administration significantly promoted serotonergic and corticospinal fiber plasticity. Nine of the 14 studies reporting on functional outcomes found that ChABC administration, alone or in combination with other treatments, including rehabilitation, improved motor function. Conclusion: The specification of anatomical changes associated with ChABC treatment can explain the functional improvements reported with its use in SCI. The limited studies on more clinically relevant contusion and compression injury models warrant further investigation of these models and alternative treatment phases. Highlights: The current study evaluates the histological effects of Chondroitinase ABC (ChABC) injection into the spinal cord in rat models of spinal cord injury (SCI).Acute-phase administration of ChABC significantly reduced cyst formation and enhanced tissue preservation.It also promoted plasticity and regeneration of sensory neurons.Across all phases, ChABC enhanced serotonergic and corticospinal fiber sprouting, suggesting broad regenerative effects.The anatomical changes induced by ChABC have important implications for SCI treatment strategies. Plain Language Summary: When the spinal cord is injured, it can cause serious problems with movement and feeling. Scientists are searching for ways to help the body repair itself after such injuries. This study looked at many earlier experiments that used a special substance called ChABC, which helps clean and fix the damaged part of the spine. The researchers reviewed the results of 17 studies on animals. They discovered that when ChABC was given soon after the injury, it stopped large scars from forming and helped protect the healthy parts of the spinal cord. It also allowed new nerves to grow and reconnect, making it easier for the body to heal and work better again. These positive effects were seen whether the treatment was given early or later after the injury. Overall, using ChABC helped the spinal cord recover better and improved nerve repair in animals. Scientists believe that it could one day help people with spinal injuries, but more research is still needed to make sure it is safe and effective for humans.

Indexed as

Chondroitinase ABCFunctional outcomeHistopathologySpinal cord injuries (SCIs)

Identifiers

PMID42222550
PMCPMC13220671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.